Healthcare / BiotechnologyNasdaqGM
$3.98
-0.31 (-7.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-101.3M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$233M
P/E
N/A
•EV/EBITDA
N/A
•ROE
68.5%
↑Gross Margin
N/A
•Debt/Equity
-0.38
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-278.7%
FCF / Net income
1.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.9M · net income $-74.3M · FCF $-86.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $30.9M | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430000.00 | — |
| Net Income | $-74.3M | $-74.3M | $-86.6M | $-98.4M | $-108.9M | $-101.3M | $-68.8M | $-51.1M |
| EBITDA | $-78.8M | $-78.8M | $-97.2M | $-104.5M | $-113.8M | $-97.5M | $-67.2M | $-50.4M |
| EPS | — | — | -1.58 | -2.34 | -2.62 | -2.73 | -6.23 | — |
| Operating Margin | -265.6% | -265.6% | -443.7% | -315.9% | -609.2% | -7637.1% | -15937.4% | — |
| Net Margin | -240.3% | -240.3% | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% | — |
| Balance Sheet | ||||||||
| Debt/Equity | -0.38 | -0.38 | -0.82 | -0.58 | 459.88 | 0.00 | 0.13 | -0.12 |
| Current Ratio | 2.92 | 2.92 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-86.1M | $-86.1M | $-101.3M | $-119.3M | $192.4M | $-53.6M | $-47.5M | $-47.3M |
| Returns | ||||||||
| ROE | 68.5% | 68.5% | 190.3% | 127.5% | -97216.1% | -104.6% | -47.1% | 58.1% |
| Valuation | ||||||||
| P/B | — | — | — | — | 2402.65 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 36.8% | 36.8% | -33.8% | 77.6% | — | 206.7% | — | — |
| EPS Growth | — | — | 32.5% | 10.7% | — | 56.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.58 → n/d
Residual
-2.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.